# US 2014/0271456 A1 · Radiotracer imaging using sodium iodide symporter polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271456 A1
- Document ID: US20140271456A1
- Status: Published application
- Kind: A1
- Application number: 14/209,369
- Filed: 2014-03-13
- Published: 2014-09-18
- Earliest claimed: 2013-03-15
- Assignees: Mayo Foundation for Medical Education and Research
- Applicants: Mayo Foundation for Medical Education and Research
- Inventors: Stephen James Russell; Kah-Whye Peng; Patrycja Lech
- Web page: https://patentgrep.com/patent/US20140271456A1

## CPC

- C07K 14/4702: {Regulators; Modulating activity}
- A61K 51/00: Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K 51/02: characterised by the carrier {, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus}
- A61K 51/025: {inorganic Tc complexes or compounds}
- A61K 51/12: characterised by a special physical form, e.g. emulsion, microcapsules, liposomes {, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules (liposomes A61K51/1234)}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This document provides methods and materials involved in radiotracer imaging using NIS polypeptides. For example, methods and materials for performing imaging techniques that increase the detection sensitivity and resolution of radiotracers localized by NIS reporter gene expression and/or decrease background signals that can be attributed to endogenously expressed NIS polypeptides are provided.

## Claims

### Claim 1

A method of imaging an animal comprising cells expressing a NIS transgene, wherein said method comprises:
(a) administering two or more gamma-emitting NIS radiotracers to said animal,
(b) collecting imaging data during a single imaging session using at least two energy windows that distinguish the gamma emissions of said two or more radiotracers to obtain at least two gamma emission datasets,
(c) subtracting one of said at least two gamma emission datasets from another of said at least two gamma emission datasets to obtain a resulting dataset capable of being used to generate subtraction images for visual or other analysis.

### Claim 2 (depends on 1)

The method of claim 1, wherein one of said at least two gamma emission datasets is pseudo-colored in one color, another of said at least two gamma emission datasets is pseudo-colored in another color, and wherein said at least gamma emission datasets are digitally merged to generate one or more pseudo-color images for visual analysis.

### Claim 3 (depends on 1)

The method of claim 1, wherein said NIS transgene encodes a mutated NIS polypeptide with diminished capacity to concentrate one or more NIS radiotracers.

### Claim 4 (depends on 1)

The method of claim 1, wherein said NIS transgene encodes a mutated NIS polypeptide with diminished capacity to concentrate pertechnetate.

### Claim 5 (depends on 4)

The method of claim 4, wherein said mutant NIS polypeptide is NIS-93E.

### Claim 6

A method of imaging an animal comprising cells expressing a NIS transgene, wherein said method comprises:
(a) administering a gamma-emitting or positron-emitting NIS radiotracer to said animal,
(b) administering non-radioactive perchlorate anions to said animal in a dose sufficient to substantially inhibit the uptake of said radiotracer by endogenous NIS-expressing cells, and
(c) collecting imaging data from said animal.

### Claim 7 (depends on 6)

The method of claim 6, wherein said NIS transgene encodes a mutated NIS polypeptide whose ability to concentrate NIS radiotracers has reduced susceptibility to perchlorate inhibition in comparison to a non-mutated NIS polypeptide.

### Claim 8

A method for imaging a mammal to reduce background from cells endogenously expressing a wild type NIS polypeptide within the stomach of said mammal, wherein said method comprises obtaining an image of radioisotope signals from a radioisotope present within said mammal, wherein said image is obtained within four hours of said mammal ingesting a contrast agent, wherein cells outside the stomach of said mammal expressing a NIS polypeptide uptake said radioisotope.

### Claim 9 (depends on 8)

The method of claim 8, wherein said radioisotope is pertechnetate or radioiodide.

### Claim 10 (depends on 8)

The method of claim 8, wherein said contrast agent is barium sulphate.

### Claim 11

A method for imaging a mammal to reduce background from radioisotope signals from cells endogenously expressing a wild-type NIS polypeptide, wherein said mammal comprises cells endogenously expressing said wild-type NIS polypeptide and cells expressing a mutant NIS polypeptide, wherein said method comprises:
(a) obtaining a first image of radioisotope signals from a first radioisotope present within a mammal, wherein cells endogenously expressing said wild-type NIS polypeptide within said mammal uptake said first radioisotope to a greater extent than cells expressing said mutant NIS polypeptide,
(b) obtaining a second image of radioisotope signals from a second radioisotope present within a mammal, wherein cells endogenously expressing said wild-type NIS polypeptide within said mammal and cells expressing said mutant NIS polypeptide within said mammal uptake said second radioisotope, and
(c) removing radioisotope signals of said first image from the radioisotope signals of said second image to obtain a final image.

### Claim 12 (depends on 11)

The method of claim 11, wherein said mammal is a human.

### Claim 13 (depends on 11)

The method of claim 11, wherein said wild-type NIS polypeptide is a human NIS polypeptide.

### Claim 14 (depends on 11)

The method of claim 11, wherein said mutant NIS polypeptide is a NIS-93E polypeptide or a NIS-93Q polypeptide.

### Claim 15 (depends on 11)

The method of claim 11, wherein said mutant NIS polypeptide is a NIS-93E polypeptide.

### Claim 16 (depends on 11)

The method of claim 11, wherein said first radioisotope is pertechnetate.

### Claim 17 (depends on 11)

The method of claim 11, wherein said second radioisotope is radioiodide.

### Claim 18 (depends on 11)

The method of claim 11, wherein cells expressing said mutant NIS polypeptide within said mammal do not uptake said first radioisotope.

### Claim 19 (depends on 11)

The method of claim 11, wherein cells endogenously expressing said wild-type NIS polypeptide and cells expressing said mutant NIS polypeptide uptake said second radioisotope with substantially different efficiencies.

### Claim 20 (depends on 11)

The method of claim 11, wherein method comprises removing substantially all radioisotope signals of said first image from the radioisotope signals of said second image to obtain said final image.
